Dexamethasone inhibits immunoreactivity of dendritic cells in patients with chronic idiopathic thrombocytopenic purpura

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 6, 2010, Pages 564-567

  Chu, Xiao Xia ^a   Huang, Bao Hua ^a   Zhang, Xiao Lu ^a   Chen, Li Ming ^a   Wang, Yan ^a   Yu, Wei Juan ^a   Wang, Xiao Lei ^a   Qin, You Ping ^a  

^a YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

cytokines; dendritic cells; dexamethasone; idiopathic thrombocytopenic purpura

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; DEXAMETHASONE; INTERLEUKIN 12P70; MEMBRANE ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG INHIBITION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOREACTIVITY; LEUKOCYTE COUNT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, SURFACE; CASE-CONTROL STUDIES; DENDRITIC CELLS; DEXAMETHASONE; FEMALE; HUMANS; INTERLEUKIN-12; LEUKOCYTES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; YOUNG ADULT;

EID: 77955919645     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32833c2b8c     Document Type: Article

References (26)

1. Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 2005; 56:425-442.
2. Garcia-Suarez J, Prieto A, Reyes E, Manzano L, Merino JL, Alvarez-Mon M. The clinical outcome of autoimmune thrombocytopenic purpura patients is related to their T cell immunodeficiency. Br J Haematol 1993; 84:464-470.
3. Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003; 349:831-836.
4. Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol 2004; 83:764-768.
5. Gutié rrez-Espíndola GR, Morales-Polanco MR, Guerrero-Rivera S, Talavera JO, Sá nchez-Valle E, Gó mez-Morales E, et al. High doses of dexamethasone in adult patients with idiopathic thrombocytopenic purpura. Arch Med Res 2003; 34:31-34.
6. Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109:1401-1407.
7. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811.
8. Groux H, Fournier N, Cottrez F. Role of dendritic cells in the generation of regulatory T cells. Semin Immunol 2004; 16:99-106.
9. Khan S, Greenberg JD, Bhardwaj N. Dendritic cells as targets for therapy in rheumatoid arthritis. Nat Rev Rheumatol 2009; 5:566-571.
10. Jara LJ, Benitez G, Medina G. Prolactin, dendritic cells, and systemic lupus erythematosus. Autoimmun Rev 2008; 7:251-255.
11. Ling Y, Cao XS, Yu ZQ, Qiu GQ, Ruan CG. Alteration and biological significance of peripheral dendritic cells in patients with chronic idiopathic thrombocytopenic purpura. Zhonghua Xue Ye Xue Za Zhi 2008; 29:187-191.
12. Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol 2007; 79:310-316.
13. Zhang XL, Peng J, Sun JZ, Guo CS, Yu Y, Wang ZG, et al. Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura. J Thromb Haemost 2008; 6:158-165.
14. Hsu NC, Chung CY, Horng HC, Chang CS. Corticosteroid administration depresses circulating dendritic cells in ITP patients. Platelets 2004; 15:451-454.
15. Catani L, Fagioli ME, Tazzari PL, Ricci F, Curti A, Rovito M, et al. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol 2006; 34:879-887.
16. Ogawara H, Handa H, Morita K, Hayakawa M, Kojima J, Amagai H, et al. High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2003; 71:283-288.
17. Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou GL, Zoumbos NC, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004; 103:2645-2647.
18. Andersson PO, Wadenvik H. Chronic idiopathic thrombocytopenic purpura (ITP): molecular mechanisms and implications for therapy. Expert Rev Mol Med 2004; 6:1-17.
19. Olsson B, Andersson PO, Jernås M, Jacobsson S, Carlsson B, Carlsson LM, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9:1123-1124.
20. Guo C, Chu X, Shi Y, He W, Li L, Wang L, et al. Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 2007; 27:557-562.
21. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998; 70:83-243.
22. Brzoza KL, Rockel AB, Hiltbold EM. Cytoplasmic entry of Listeria monocytogenes enhances dendritic cell maturation and T cell differentiation and function. J Immunol 2004; 173:2641-2651.
23. Winzler C, Rovere P, Rescigno M, Granucci F, Penna G, Adorini L, et al. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 1997; 185:317-328.
24. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13:4677-4685.
25. Cernadas M, Lu J, Watts G, Brenner MB. CD1a expression defines an interleukin-12 producing population of human dendritic cells. Clin Exp Immunol 2009; 155:523-533.
26. Henry CJ, Ornelles DA, Mitchell LM, Brzoza-Lewis KL, Hiltbold EM. IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. J Immunol 2008; 181:8576-8584.